The short version of REV-ERB agonist fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-01-22. Anything still debated is marked as such rather than presented as settled.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to pale yellow solid | Visual description varies with purity and source |
| Solubility | Soluble in DMSO and ethanol; poorly soluble in water | Organic stock solutions are common in research |
| Typical storage | -20 °C, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Typical analytical method | LC-MS or HPLC-UV | Reference standards are needed for quantification |
| Molar mass | Approximately 437.9 g/mol | Calculated from the reported free-base formula |
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
=== Cited texts === Benjamin, Denis R. (1995). Mushrooms: Poisons and Panaceas—A Handbook for Naturalists, Mycologists and Physicians. New York: WH Freeman and Company. ISBN 978-0-7167-2600-5. Jordan, Peter; Wheeler, Steven (2001). The Ultimate Mushroom Book. London: Hermes House. ISBN 978-1-85967-092-7. Zeitlmayr, Linus (1976). Wild Mushrooms: An Illustrated Handbook. Hertfordshire: Garden City Press. ISBN 978-0-584-10324-3.
==== Insecticides ==== RNAi is under development as an insecticide, employing multiple approaches, including genetic engineering and topical application. Cells in the midgut of some insects take up the dsRNA molecules in the process referred to as environmental RNAi. In some insects the effect is systemic as the signal spreads throughout the insect's body (referred to as systemic RNAi). Animals exposed to RNAi at doses millions of times higher than anticipated human exposure levels show no adverse effects. RNAi has varying effects in different species of Lepidoptera (butterflies and moths). Drosophila spp., Bombyx mori, Locusta spp., Spodoptera spp., Tribolium castaneum, Nilaparvata lugens, Helicoverpa armigera, and Apis mellifera are models that have been widely used to learn how RNAi works within particular taxa of insects. Musca domestica has two Ago2 genes and Glossina morsitans three, as found by Lewis et al. 2016 and Hain et al. 2010. In the case of the miRNA pathway Diuraphis noxia has two Ago1s, M. domestica two Dcr1s, Acyrthosiphon pisum two each of Ago1 and Loqs and Dcr1 and four of Pasha. While in the piRNA, G. morsitans and A. pisum have two or three Ago3s each. This has led to identification of future insecticide development targets, and the modes of action and reasons for insecticide resistance of other insecticides.
== Methods == Prohibited methods include manipulation of blood components (e.g. autologous red blood cell transfer, "blood doping"), manipulation of samples, and gene doping. These are prohibited at all times.
=== Structural evolution === De novo proteins typically exhibit less well-defined secondary and three-dimensional structures, often lacking rigid folding but having extensive disordered regions. Quantitative analyses are still lacking on the evolution of secondary structural elements and tertiary structures over time. As structure is usually more conserved than sequence, comparing structures between orthologs could provide deeper insides into de novo gene emergence and evolution and help to confirm these genes as true de novo genes. Nevertheless, so far only very few de novo proteins have been structurally and functionally characterized, especially due to problems with protein purification and subsequent stability. Progresses have been made using different purification tags, cell types and chaperones. The 'antifreeze glycoprotein' (AFGP) in Arctic codfishes prevents their blood from freezing in arctic waters. Bsc4, a short non-essential de novo protein in yeast, has been shown to be built mainly by β-sheets and has a hydrophobic core. It is associated to DNA repair under nutrient-deficient conditions. The Drosophila de novo protein Goddard has been characterized for the first time in 2017. Knockdown Drosophila melanogaster male flies were not able to produce sperm. Recently, it could be shown that this lack was due to failure of individualization of elongated spermatids.
=== Ed Conner === Ed Conner is played by Ned Beatty. Ed is Dan's father, a charming traveling salesman who always brings presents for the grandchildren. Dan has a troubled history with his father, and Roseanne tries to keep the peace between the two. The family likes Ed, but Dan grew up feeling neglected with Ed seldom being home and his mother's mental illness, in addition to verbal slights that Ed targets towards Dan (e.g., when Dan questions Ed dating Crystal, Ed makes a rude crack about Dan being "interested" in Crystal). It usually takes little to no time for Dan to become annoyed by his father's presence. All this was unknown to Dan until Crystal revealed it to Roseanne. Ed hoped to provide Dan with at least one stable parent as he would often be gone on sales trips during Dan's adolescence. He wants to learn from his past actions and be a better father and husband. He loves his son despite their troubled relationship, and also loves the rest of his family. He marries Crystal and has two children with her (Ed Jr. and Angela), who are significantly younger than their half-brother, Dan. He is said to have died in The Conners; it appears he was no longer with Crystal and was living alone.
Sources: en.wikipedia.org
== Research == The steroidal antiandrogen cyproterone acetate has been studied for blocking the testosterone flare at the start of buserelin therapy in men with prostate cancer. While cyproterone acetate for two weeks eliminates the biological and biochemical signs of the flare, no benefits on prostate cancer outcomes were observed. Very low doses of buserelin nasal spray have been assessed for increasing testosterone levels and fertility in men with oligoasthenozoospermia and hypogonadotropic hypogonadism.
These discoveries led numerous countries to begin working on the development of nuclear weapons and nuclear power. Despite fission having been discovered in Germany, the Uranverein ("uranium club") Germany's wartime project to research nuclear power and/or weapons was hampered by limited resources, infighting, the exile or non-involvement of several prominent scientists in the field and several crucial mistakes such as failing to account for impurities in available graphite samples which made it appear less suitable as a neutron moderator than it is in reality. Germany's attempts to build a natural uranium / heavy water reactor had not come close to reaching criticality by the time the Americans reached Haigerloch, the site of the last German wartime reactor experiment. On 2 December 1942, as part of the Manhattan Project, another team led by Enrico Fermi was able to initiate the first artificial self-sustained nuclear chain reaction, Chicago Pile-1. An initial plan using enriched uranium-235 was abandoned as it was as yet unavailable in sufficient quantities. Working in a lab below the stands of Stagg Field at the University of Chicago, the team created the conditions needed for such a reaction by piling together 360 tonnes of graphite, 53 tonnes of uranium oxide, and 5.5 tonnes of uranium metal, most of which was supplied by Westinghouse Lamp Plant in a makeshift production process.
Gender incongruence is marked and sustained Patient meets diagnostic criteria for gender incongruence prior to gender-affirming hormone treatment in regions where a diagnosis is necessary to access health care Patient has capacity to consent to hormone therapy treatment Other possible causes of apparent gender incongruence have been identified and excluded Mental health and physical conditions that could negatively impact the outcome of treatment have been assessed Understands the effect of gender-affirming hormone treatment on reproduction and they have explored reproductive options The WPATH standards of care distinguish between gender-affirming hormone therapy, and hormone replacement therapy, with the latter referring to the replacement of endogenous hormones after a gonadectomy to prevent cardiovascular and musculoskeletal issues.
Created by writer Chris Claremont, Elizabeth "Betsy" Braddock first appeared in Captain Britain #8 (December 1976), with Captain Britain #10 (December 1976) as her first cover appearance, published by the Marvel Comics' British imprint Marvel UK. In New Mutants Annual #2 (1986), Claremont integrated Betsy Braddock into the X-Men franchise. After being rescued by the New Mutants and taking up residence at their mutant-training academy, Braddock is formally invited to join the X-Men and officially adopts the codename Psylocke, becoming an enduring fixture of the team over the next three decades. In Uncanny X-Men #213 (January 1987), Psylocke battles Sabretooth, demonstrating her fighting skills by holding him at bay. In Uncanny X-Men #256 (December 1989), an amnesiac Betsy is kidnapped by the Hand, who brainwash her and physically alter her to take on an East Asian appearance. Under the name Lady Mandarin, she briefly becomes the Hand's supreme assassin. While her memories return, she retains her new appearance and skills, including the ability to manifest the focused totality of her telepathic power in the form of a “psychic knife.” The art for Psylocke's redesigned costume is by Jim Lee. In a later interview, he describes the creative process:
=== Biosynthesis === In plants and microorganisms, isoleucine is synthesized from pyruvate and alpha-ketobutyrate. This pathway is not present in humans. Enzymes involved in this biosynthesis include:
Sources: en.wikipedia.org
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.
The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.
Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.